Management of Drug-Resistant Tuberculosis in Pregnancy: Epidemiology, Challenges, and Treatment Strategies
Keywords:
Drug-resistant tuberculosis, pregnancy, Smart4TB, Beat-TB, bedaquiline, bedaquilinedelamanid, pulmonologists, neonatal healthAbstract
Pregnancy-related drug-resistant TB poses several difficulties because of the complicated treatment plans, teratogenicity hazards, and the paucity of safety evidence on second-line TB medications. Research trials frequently leave pregnant women out, resulting in a lack of evidence-based recommendations for treating DR-TB. Increased morbidity, premature birth, and low birth weight are just a few of the major health problems the illness poses to both the mother and the newborn. Newer medications like delamanid and bedaquiline have shown encouraging safety profiles during pregnancy, and recent studies have concentrated on improving treatment approaches. To bridge the knowledge gap, recent clinical trials that include pregnant individuals include Smart4TB and Beat-TB. The World Health Organization (WHO) has started to address this problem by updating recommendations to encourage the use of more recent, all-oral regimens. To improve the outcomes for mothers and newborns, a multidisciplinary strategy comprising obstetricians, pulmonologists, and infectious disease specialists is essential. To improve treatment adherence, psychosocial and nutritional assistance are also crucial. Future studies should further include pregnant women in clinical trials to ensure safer and more efficient methods of treating DR-TB during pregnancy.
Downloads
Metrics
References
World Health Organization. WHO Global Task Force on TB Impact Measurement: report of a subgroup meeting on methods used by WHO to estimate TB disease burden, 11-12 May 2022, Geneva, Switzerland. World Health Organization; 2022 Oct 10.
World Health Organization. Global tuberculosis report 2021: supplementary material. World Health Organization; 2022 Mar 31.
Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The lancet Respiratory medicine. 2017 Apr 1;5(4):291-360.
Migliori GB, et al. Eur Respir J. 2020;55(6):1902106. Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D'Ambrosio L, Centis R, Sotgiu G, Menegale O, Kliiman K. European union standards for tuberculosis care.
Parums DV. updates from the World Health Organization (WHO) on global treatment recommendations for drug-susceptible and multidrug-resistant tuberculosis. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2021 Aug 9;27:e934292-1. WHO. Multidrug-resistant tuberculosis: 2021 update. Geneva: WHO; 2021.
Palacios E, Dallman R, Muñoz M, Hurtado R, Chalco K, Guerra D, Mestanza L, Llaro K, Bonilla C, Drobac P, Bayona J. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clinical infectious diseases. 2009 May 15;48(10):1413-9.
Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clinical infectious diseases. 2012 Dec 1;55(11):1532-49.
Loveday M, Sunkari B, Marais BJ, Master I, Brust JC. Dilemma of managing asymptomatic children referred with ‘culture-confirmed’drug-resistant tuberculosis. Archives of disease in childhood. 2016 Jul 1;101(7):608-13.
Gupta A, et al. Maternal tuberculosis: a risk factor for perinatal mortality. Lancet Glob Health. 2014;2(9):e537-46.
Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532-49
World Health Organization. WHO Global Task Force on TB Impact Measurement: report of a subgroup meeting on methods used by WHO to estimate TB disease burden, 11-12 May 2022, Geneva, Switzerland. World Health Organization; 2022 Oct 10.
Loveday M, et al. Maternal and infant outcomes among pregnant women treated for multidrug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis. 2016;20(12):1610-14.
Singh N, et al. Maternal and perinatal outcomes in pregnant women with tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis. 2016;20(3):362-70.
Sinha P, et al. Predictors of multidrug-resistant tuberculosis in children and adolescents: a systematic review and meta-analysis. Clin Microbiol Rev. 2020;33(3):e00129-19.
Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13(11):1320-30.
Ramaswamy SV, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998;79(1):3-29.
Campbell EA, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104(6):901-12.
Ginsburg AS, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: Mechanisms and implications for treatment. Clin Infect Dis. 2003;37(8):1103-9
Zaunbrecher MA, et al. Eis, an aminoglycoside acetyltransferase from Mycobacterium tuberculosis, confers resistance to kanamycin and amikacin. Proc Natl Acad Sci USA. 2009;106(47):20004-9.
Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: Epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532-49.
Theron G, et al. The diagnostic accuracy of the GeneXpert MTB/RIF assay for pulmonary tuberculosis in a high HIV prevalence setting: A prospective study. PLoS Med. 2011;8(7):e1001061.
Boehme CC, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005-15.
Hillemann D, et al. Rapid molecular detection of extrapulmonary tuberculosis by the Genotype MTBDRplus assay. J Clin Microbiol. 2007;45(5):1476-9.
Walker TM, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: A retrospective cohort study. Lancet Infect Dis. 2015;15(10):1193-202.
Nahid P, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-resistant tuberculosis. Clin Infect Dis. 2019;69(7):1117-1140.
Shin S, et al. Treatment outcomes in patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(8):440-9.
World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment: online annexes. InWHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment: online annexes 2020.
Chen CY, et al. Safety of fluoroquinolones in pregnant women: a meta-analysis. Clin Infect Dis. 2021;72(1):e96-e106.
Sturkenboom MC, et al. Drug safety in pregnancy: the fluoroquinolone example. Pharmacoepidemiol Drug Saf. 2008;17(9):897-901.
Pontali E, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2017;49(4):1601815.
Modongo C, et al. Successful pregnancy outcomes in women treated for multidrug-resistant tuberculosis in Botswana. Int J Tuberc Lung Dis. 2014;18(9):1059-64.
Lerner SA, et al. Ototoxicity and nephrotoxicity of aminoglycosides: A review. J Infect Dis. 1981;144(1):3-8.
World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: WHO; 2020.
Tunkel AR, et al. Aminoglycoside nephrotoxicity: Risk factors and mechanisms of injury. Antimicrob Agents Chemother. 2003;47(3):929-40.
Domachowske JB, et al. Effects of fluoroquinolones on pediatric cartilage: Implications for treatment of multidrug-resistant tuberculosis. Pediatr Infect Dis J. 1998;17(4):287-9
Padberg S, et al. Safety of fluoroquinolone use during pregnancy: A meta-analysis of observational studies. Clin Infect Dis. 2021;72(8):1442-51.
Mathad JS, Gupta A. Tuberculosis in pregnancy: Epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532-49.
Tran JH, et al. Rifampin-drug interactions: A systematic review. Clin Pharmacokinet. 2020;59(2):143-58
Van Ingen J, et al. Fluoroquinolones in tuberculosis treatment: WHO recommendations and recent developments. Int J Antimicrob Agents. 2012;39(2):112-20.
Pontali E, et al. Bedaquiline and multidrug-resistant tuberculosis: A systematic review. Eur Respir J. 2017;49(4):1601815.
Skripconoka V, et al. Delamanid improves outcomes in multidrug-resistant tuberculosis. Eur Respir J. 2013;41(6):1393-400.
Duggal P, et al. Aminoglycoside toxicity: A review of nephrotoxicity and ototoxicity. Clin Kidney J. 2021;14(1):1-9.
Padberg S, et al. Safety of fluoroquinolone use during pregnancy: A meta-analysis of observational studies. Clin Infect Dis. 2021;72(8):1442-51.
Guglielmetti L, et al. QT prolongation and cardiac toxicity in patients treated with bedaquiline and delamanid. Emerg Infect Dis. 2018;24(3):491-94
Courtwright A, Turner AN. Tuberculosis and stigmatization: Pathways and interventions. Public Health Rep. 2010;125(Suppl 4):34-42.
Datiko DG, et al. The impact of stigma on treatment adherence among TB patients: A systematic review. BMC Infect Dis. 2020;20(1):1-12.
Sweetland AC, et al. Depression: A silent driver of the TB epidemic. Int J Tuberc Lung Dis. 2017;21(7):S6-S10.
Ukwaja KN, et al. Health care financing for TB patients in developing countries: A systematic review. PLoS Med. 2013;10(2):e1001316.
Horter S, et al. “I can also serve as an inspiration”: A qualitative study of the TB & HIV treatment-seeking experiences of patients diagnosed with multidrug-resistant tuberculosis in South Africa. PLoS One. 2020;15(5):e0233459.
World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment: online annexes. InWHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment: online annexes 2020.
Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clinical infectious diseases. 2012 Dec 1;55(11):1532-49.
Shin S, et al. Adverse effects of second-line anti-tuberculosis drugs in multidrug-resistant TB treatment: A systematic review. Lancet Infect Dis. 2008;8(8):440-9.
Ahmad N, et al. Treatment of multidrug-resistant tuberculosis: An updated WHO guideline-based approach. Clin Microbiol Infect. 2021;27(1):139-48.
Pontali E, et al. Bedaquiline- and delamanid-containing regimens for multidrug-resistant tuberculosis: A systematic review and meta-analysis. Eur Respir J. 2017;49(4):1601815.
World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4 – Treatment: Drug-resistant tuberculosis treatment. Geneva: WHO; 2020.
Pontali E, et al. Bedaquiline-containing regimens improve treatment outcomes in multidrug-resistant tuberculosis: A systematic review. Eur Respir J. 2017;49(4):1601815.
Ahmad N, et al. WHO’s updated approach to MDR-TB treatment: The role of new drugs. Clin Microbiol Infect. 2021;27(1):139-48.
Hwang H, Kang H, Kwon YS, Jeon D, Shim TS, Yim JJ. Outcomes of multidrug-resistant tuberculosis treated with bedaquiline or delamanid. Clinical Infectious Diseases. 2021 Oct 15;73(8):1362-9
Espinal MA, et al. The impact of multidrug-resistant tuberculosis on maternal and perinatal outcomes. Int J Tuberc Lung Dis. 2017;21(7):791-97.
Nunes JT, et al. Malnutrition and tuberculosis: A syndemic perspective in pregnancy. Eur J Clin Nutr. 2020;74(2):264-72.
Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. American journal of respiratory and critical care medicine. 2019 Nov 15;200(10):e93-142.
World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. World Health Organization; 2022 Nov 30.
Sugarman J, et al. Multidisciplinary care models for tuberculosis in pregnancy: A global perspective. Lancet Infect Dis. 2021;21(5):e103-e112.
World Health Organization. Nutritional care and support for patients with tuberculosis. Geneva: WHO; 2013.
Bhargava A, Chatterjee M, Jain Y, Chatterjee B, Kataria A, Bhargava M, Kataria R, D’Souza R, Jain R, Benedetti A, Pai M. Nutritional status of adult patients with pulmonary tuberculosis in rural central India and its association with mortality. PloS one. 2013 Oct 24;8(10):e77979.
Courtwright A, Turner AN. Tuberculosis and stigmatization: pathways and interventions. Public health reports. 2010 Jul;125(4_suppl):34-42.
Sweetland AC, Kritski A, Oquendo MA, Sublette ME, Norcini Pala A, Silva LR, Karpati A, Silva EC, Moraes MO, Silva JR, Wainberg ML. Addressing the tuberculosis–depression syndemic to end the tuberculosis epidemic. The International Journal of Tuberculosis and Lung Disease. 2017 Aug 1;21(8):852-61.
Horter S, et al. The role of family and social support in TB treatment adherence: A qualitative study. PLoS One. 2020;15(5):e0233459.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
